



7



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed


Andrew Gersy

Dated

25th May 2001



Patents Act 1977
(Rule 16)



05MAY00 E534536-1 D10059

P01/7700-0.00-0010856.3

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
South Wales
NP9 1RH

1. Your reference

CIP-1

2. Patent application number

(The Patent Office will fill in this part)

0010856.3

3. Full name, address and postcode of the or of each applicant (underline all surnames)

K.U.Leuven R&D - Groot Begijnhof - Benedenstraat 59 - 3000 Leuven

Represented by Prof. dr. ir. K. Debackere, Managing Director and Hans Claes, Director

Patents ADP number (if you know it)

7665649001

If the applicant is a corporate body, give the country/state of its incorporation

4. Title of the invention

Insulin related methods or preparations for suppressing states of
"Critical Illness Polyneuropathy"

5. Name of your agent (if you have one)

"Address for service" in the United Kingdom
to which all correspondence should be sent
(including the postcode)

K.U.Leuven R&D

Care Off:

Dominique Newman

Quartz Capital Limited

3 St. James's Square

London SW1Y 4JU

7816093001

Patents ADP number (if you know it)

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

See note (d))


Yes

Pat nts Form 1/77

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form



Description 7 ✓
 Claim(s) 2 ✓
 Abstract 1 ✓
 Drawing(s) 0

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77) 1

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

1 fax cover sheet

1 fee sheet with request for fax back service

I/We request the grant of a patent on the basis of this application.

11.
 Hans Claes
 Director

Prof. dr. ir. K. Debackere
 Managing Director

Signature

Date

05/05/2000

12. Name and daytime telephone number of person to contact in the United Kingdom

Dominique Newman
 tel. 0171 766 2900 or 0207 766 2900

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

Patents Form 1/77

**INSULIN RELATED METHODS OR PREPARATIONS FOR SUPPRESSING STATES OF
'CRITICAL ILLNESS POLYNEUROPATHY'**

*G. Van den Berghe MD, PhD
Dept. Intensive Care Medicine
Catholic University of Leuven
Leuven B-3000
BELGIUM*

TECHNOLOGICAL BACKGROUND

A specific type of polyneuropathy develops in patients that are treated within an intensive care unit (ICU) for several days to weeks and this for a variety of primary injuries or illnesses. This polyneuropathy, known as "Critical Illness Polyneuropathy" (CIPNP) occurs in 70% of patients who have the systemic inflammatory response syndrome (SIRS) (Zochodne DW et al. 1987 Polyneuropathy associated with critical illness : a complication of sepsis and multiple organ failure. Brain, 110: 819-842); (Leijten FSS & De Weerd AW 1994 Critical illness polyneuropathy: a review of the literature, definition and pathophysiology. Clinical Neurology and Neurosurgery, 96: 10-19). However, clinical signs are often absent and it remains an occult problem in many ICUs worldwide. Nonetheless, it is an important clinical entity as it a frequent cause of difficulty to wean patients from the ventilator and it leads to problems with rehabilitation after the acute illness has been treated and cured.

When CIPNP is severe enough, it causes limb weakness and reduced tendon reflexes. Sensory impairment follows but is difficult to test in ICU patients. Electrophysiological examination (EMG) is necessary to establish the diagnosis (Bolton CF. 1999 Acute Weakness. In: Oxford Textbook of Critical Care; Eds. Webb AR, Shapiro MJ, Singer M, Suter PM; Oxford Medical Publications, Oxford UK; pp. 490-495). This examination will reveal a primary axonal degeneration of first motor and then sensory fibers. Phrenic nerves are often involved. Acute and

chronic denervation has been confirmed in muscle biopsies of this condition. If the underlying condition (sepsis or SIRS) can be successfully treated, recovery from the CIPNP can be expected. This will occur in a matter of weeks in mild cases and in months in more severe cases. In other words, the presence of CIPNP can delay the weaning and rehabilitation for weeks or months.

The pathophysiology of this type of neuropathy remains unknown (Bolton CF 1996 Sepsis and the systemic inflammatory response syndrome: neuromuscular manifestations. Crit Care Med. 24: 1408-1416). It has been speculated to be directly related to sepsis and its mediators. Indeed, cytokines released in sepsis have histamine-like properties which may increase microvascular permeability. The resulting endoneural edema could induce hypoxia, resulting in severe energy deficits and hereby primary axonal degeneration. Alternatively, it has been suggested that cytokines may have a direct cytotoxic effect on the neurons. Contributing factors to disturbed microcirculation are the use of neuromuscular blocking agents and steroids. Moreover, a role for aminoglycosides in inducing toxicity and CIPNP has been suggested. However, there is still no statistical proof for any of these mechanisms in being a true causal factor in the pathogenesis of CIPNP.

Although polyneuropathy of critical illness was first described in 1985 by three different investigators, one Canadian, one American, and one French, to date there is no effective treatment to prevent or stop Critical Illness Polyneuropathy.

SUMMARY OF THE INVENTION

This invention was based on the discovery that CIPNP can be prevented, to a certain extent, by strictly controlling glucose metabolism during critical illness by applying intensive insulin treatment with clamping of blood glucose levels within the normal range (80-110 mg/dL). To date the current standard of practice of care was that within the settings of good clinical ICU practice, blood glucose levels are allowed to increase as high as to 250 mg/dL or there above. The reason for this permissive attitude is the thought that high levels of blood glucose are part of the adaptive stress responses, and thus do not require treatment unless extremely elevated (Mizock BA. Am J Med 1995; 98: 75-84). Also, relative hypoglycaemia during stress is thought

to be potentially deleterious for the immune system and for healing (Mizock BA. Am J Med 1995; 98: 75-84)

This invention demonstrates that clamping of blood glucose levels within normal limits (80 to 110 mg/dL) in chronic ill patients can be used to significantly reduce the incidence of CIPNP and to lengthen the time free of CIPNP in patients that do develop this problem.

In the illustrative embodiment of present invention blood glucose levels were controlled by insulin treatment. However after this invention, it will be clear for the man skilled in the art that also active insulin derivatives and its physiologically tolerated salts can be used to obtain the same outcome.

Furthermore it will be clear for the man skilled in the art compounds of the group of biologically active substances having insulin releasing action can be used to treat Critical Illness Polyneuropathy or to manufacture a medicine to treat Critical Illness Polyneuropathy. Such compound with an activity of promoting the secretion of insulin were already well disclosed before the moment of this invention such as the Islets-Activating Proteins (Ui; Michio et al US5000953 March 19, 1991) and the glucagon-like peptides (Habener; Joel F. Newton Highlands, MA US5614492 March 25, 1997)

Furthermore it will be clear for the man skilled in the art compounds of the group of compounds that stimulate signal transduction mediated by an insulin receptor type tyrosine kinase in a cell can be used to treat or to manufacture a medicine to treat Critical Illness Polyneuropathy. It was well known before the date of this invention that insulin binding to the insulin receptor triggers a variety of metabolic and growth promoting effects. Metabolic effects include glucose transport, biosynthesis of glycogen and fats, inhibition of triglyceride breakdown, and growth promoting effects include DNA synthesis, cell division and differentiation. It is known that some of these biological effects of insulin can be mimicked by vanadium salts such as vanadates and pervanadates. However, this class of compounds appears to inhibit phosphotyrosine phosphatases generally, and are potentially toxic because they contain heavy metal (U.S. Pat. No. 5,155,031; Fantus et al., 1989, Biochem., 28:8864-

71; Swarup et al., 1982, Biochem. Biophys. Res. Commun. 107:1104-9). Moreover it had been already demonstrated (LAMMERS REINER et al 1999-01-19 US5861266 & WO9523217) that certain protein-tyrosine phosphatases (PTP's), in particular, RPTP.alpha. and RPTP.epsilon., specifically regulate the insulin receptor signalling pathway. Compounds that specifically modulate the activity of the controlling RPTP, thereby prolonging or enhancing signal transduction mediated by the insulin receptor can thus be used to treat Critical Illness Polyneuropathy or to manufacture a medicine to treat Critical Illness Polyneuropathy. Such compounds have low toxicity since they are specific for the PTPs associated with insulin receptor activity, and do not significantly affect the activity of other PTPs that are non-specific

DEFINITIONS

The term "systemic inflammatory response syndrome (SIRS)", as used herein refers to the uncontrolled disease process which ensues an initial insult and which gives rise to a multisystem disturbance secondary to inflammatory mediators released during shock.

The term "Sepsis", as used herein refers to "SIRS", as described above, which is particularly caused by an infectious insult leading to the initial shock phase.

The term "mediators of sepsis", as used herein refers to factors released by inflammatory cells, such as TNFs, interleukins, bradykinins etc.

The term "insulin receptor type tyrosine kinase", as used herein refers to a post-receptor signal transduction pathway involved in the insulin signaling.

The term "Endoneural edema", as used herein refers to swelling of the neuronal cells.

The term "phrenic nerves", as used herein refers to the left and right nervus phrenicus, innervating the diaphragm.

DESCRIPTION OF THE ILLUSTRATIVE EMBODIMENT

The terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appending claims. This invention is not limited to the particular methodology, protocols, delivery forms and reagents described as these may vary

Material and Methods

In a prospective clinical study, we tested the hypothesis that the incidence of CIPNP can be reduced by more strict metabolic using intensive insulin treatment from admission onward.

Between February 2 and April 25 2000, 400 patients were included in the study. They had been randomly allocated to one of two insulin (Actrapid HM NovoLet of Novo Nordisk) treatment schedules :

- (1) insulin infusion started at a dose of 1U/h only when blood glucose is > 230 mg/dL (13 mmol/L) and titrated up (2 to 4 hourly controls of blood glucose levels) with increments of 0.5 to 1 U/h to keep blood glucose below this level [180-200 mg/dL (10.3-11.2 mmol/L)]. When blood glucose levels reach 180 mg/dL, insulin infusion is stopped.
- (2) insulin infusion started when blood glucose is > 120 mg/dL (6.8 mmol/L) at a dose of 2 U/h and titrated up (2 to 4 hourly controls of blood glucose levels) with increments adequate to keep blood glucose levels normal and thus below this level [80-110 mg/dL (4.6-6.1 mmol/L)]. Maximal hourly insulin dose is set at 60 U per hour. When blood glucose levels reach 80 mg/dL, insulin infusion is tapered and eventually stopped until normal levels are again reached. During interruption of enteral tube feeding for determination of residual stomach content, insulin infusion is reduced proportionately to the reduction of caloric intake.

Concomitantly, patients were fed, on the admission day using a 20% glucose infusion and from day 2 onward by using a standardised feeding schedule consisting

of normal caloric intake (25-35 Calories/kgBW/24h) and balanced composition (20%-40% of the non-protein Calories as lipids & 1-2 g/kgBW/24h protein) of either total parenteral, combined parenteral/enteral or full enteral feeding, the route of administration of feeding depending on assessment of feasibility of early enteral feeding by the attending physician. All other treatments, including feeding regimens, were according to standing orders currently applied within the ICU.

Exclusion criteria were age <18y, pregnancy and not being intubated at admission.

When patients were still treated in the ICU after 7 days, a weekly EMG examination was performed to screen for the presence of CIPNP. The EMGs were always interpreted by the same expert in electrophysiology. In order to accurately assess ICU stay, which is often determined by other factors than the patient's condition -- e.g. bed availability on the wards -- "end of ICU stay" was defined as the day on which the attending physician considers the patient to be "ready for discharge".

The study protocol had been approved by the University of Leuven School of Medicine Ethical Review Board (ML1094 -- dd 26-10-99).

Results

83 patients ended up being treated on the ICU for at least one week and were screened by EMG for the presence of CIPNP. In the group randomised into the "intensive insulin schedule", 38 patients stayed for more than 7 days and in the group randomised into the "restrictive insulin schedule", 45 patients stayed more than 7 days. Fifteen out of 38 long-stay ICU patients in the intensive insulin group (or 39% of the long stayers) revealed a positive EMG for CIPNP at any time during the ICU stay versus 30 out of 45 in the restrictive insulin group (or 67%) ($P=0.01$ with Chi-square).

In the intensive insulin group, the mean \pm SD number of positive EMGs for CIPNP per patient was 0.9 ± 1.8 (median of zero) versus 1.8 ± 2.1 (median of 1) in the restrictive insulin group ($P=0.015$ with Mann-Whitney U test).

Long-stay patients in the intensive insulin group had a CIPNP-free time on the ICU of 2.1 ± 1.8 weeks versus 1.1 ± 1.2 weeks in the restrictive insulin group ($P=0.004$ with unpaired Student's t-test).

ICU-mortality was not detectably different between the two treatment groups ($P=0.4$).

CONCLUSIONS

This study revealed that strict metabolic control with intensive insulin treatment and clamping of blood glucose levels within normal limits significantly reduces the incidence of CIPNP and lengthens the time free of CIPNP in patients that do develop this problem. This is the first study to point to a preventive strategy for this frequently occurring and important problem in ICU patients. Since the presence of EMG-proven CIPNP has been shown to extend the need for ICU support and to prolong the time required for rehabilitation, this treatment will lead to a reduction in need for ICU support and to a shorter time for rehabilitation, which could reflect a major reduction in costs.

CLAIMS

What is claimed is:

1. Use of a pharmaceutically effective composition for use in the therapeutic treatment of a mammal having Critical Illness Polyneuropathy, comprising a pharmaceutically effective amount of a compound which is selected from a group of compounds comprising insulin, its active derivatives and the physiologically tolerated salts of these insulin derivatives or of a group of biologically active substances having insulin releasing action or of a group of compounds that stimulate signal transduction mediated by an insulin receptor type tyrosine kinase in a cell.
2. Use of a pharmaceutically effective composition for use in the prophylactic treatment of a mammal having Critical Illness Polyneuropathy, comprising a pharmaceutically effective amount of a compound which is selected from a group of compounds comprising insulin, its active derivatives and the physiologically tolerated salts of these insulin derivatives or of the group of biologically active substances having insulin releasing action or of the group of compounds that stimulate signal transduction mediated by an insulin receptor type tyrosine kinase in a cell.
3. Use of compounds of the group of compounds comprising insulin, its active derivatives and the physiologically tolerated salts of these insulin derivatives or of a group of biologically active substances having insulin releasing action or of a group of compounds that stimulate signal transduction mediated by an insulin receptor type tyrosine kinase in a cell for the manufacturing of a medicament for the treatment or prevention of Critical Illness Polyneuropathy
4. A method for the treatment of Critical Illness Polyneuropathy in mammals, wherein said critical ill individual receives an effective amount of a compound to keep the blood glucose levels between 80 and 110 mg/dL (4.6-6.1 mmol/L).

5. The method of claim 4 whereby said compound is selected from a group of compounds comprising insulin, its active derivatives and the physiologically tolerated salts of these insulin derivatives or of a group of biologically active substances having insulin releasing action or of a group of compounds that stimulate signal transduction mediated by an insulin receptor type tyrosine kinase in a cell

ABSTRACT

This invention relates to the pharmaceutically effective composition to treat or prevent Critical Illness Polyneuropathy. The composition comprises a pharmaceutically effective amount of a compound which is selected from a group of compounds comprising insulin, its active derivatives and the physiologically tolerated salts of these insulin derivatives or of a group of biologically active substances having insulin releasing action or of a group of compounds that stimulate signal transduction mediated by an insulin receptor type tyrosine kinase in a cell.